Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry)

Kardiologia Polska

Volumn 70, Issue 3, 2012, Pages 215-221

  Rakowski, Tomasz ^a   Siudak, Zbigniew ^a   Dziewierz, Artur ^a   Birkemeyer, Ralf ^b   Janzon, Magnus ^c   Mielecki, Waldemar ^a   Zmudka, Krzysztof ^a   Dubiel, Jacek S ^a   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b SCHWARZWALD BAAR KLINIKUM   (Germany)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Abciximab; Angioplasty; Myocardial infarction; Registries; Reperfusion

Indexed keywords

ABCIXIMAB; HEPARIN;

ADULT; AGED; ANGIOGRAPHY; ARTERY; ARTICLE; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HUMAN; INFARCT RELATED ARTERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84859015825     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008; 29: 2909-2945.
2. Kushner FG, Hand M, Smith SC Jr et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2009; 120: 2271-2306.
3. Stone GW, Cox D, Garcia E et al. Normal flow (TIMI 3)before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Analysis From the Primary Angioplasty in Myocardial Infarction Trials. Circulation, 2001; 104: 636-641.
4. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcome after primary angioplasty for acute myocardial infarction. Am J Cardiol, 2000; 85: 13-18. (Pubitemid 30045537)
5. Dudek D, Siudak Z, Janzon M et al. European registry onpatients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab: EUROTRANSFER Registry. Am Heart J, 2008; 156: 1147-1154.
6. Rakowski T, Siudak Z, Dziewierz A et al. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J, 2009; 158: 569-575.
7. Siudak Z, Rakowski T, Dziewierz A et al. Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol, 2010; 68: 539-543.
8. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet, 2006; 367: 579-588. (Pubitemid 43247573)
9. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction ASSENT-4 PCI): randomized trial. Lancet, 2006; 367: 569-578
10. Dudek D, Rakowski T, El Massri N et al. Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome. Int J Cardiol, 2008; 124: 326-331. (Pubitemid 351305379)
11. Rakowski T, Zalewski J, Legutko J et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J, 2007; 153: 360-365. (Pubitemid 46328765)
12. De Luca G, Gibson CM, Bellandi F et al. Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. Heart, 2008; 94: 1548-1558.
13. Van't Hof AW, Ten Berg J, Heestermans T et al.; Ongoing Tirofiban InMyocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet, 2008; 372: 537-546.
14. Herrmann HC, Lu J, Brodie BR et al.; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. J Am Coll Cardiol Cardiovasc Interv, 2009; 2: 917-924.
15. Ellis SG, Tendera M, de Belder MA et al.; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med, 2008; 358: 2205-2217. (Pubitemid 351724450)
16. Ortolani P, Marzocchi A, Marrozzini C et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J, 2009; 30: 33-43.
17. Huber K, Holmes DR Jr, van't Hof AW et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J, 2010; 31: 1708-1716.
18. Loubeyre C, Morice MC, Lefèvre T Piéchaud JF, Louvard Y,Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol, 2002; 39: 15-21. (Pubitemid 34059856)
19. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest, 2002; 122: 1322-1332.
20. Gibson CM, Murphy S, Menown IB et al. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol, 1999; 34: 1403-1412.
21. Jang IK, Gold HK, Ziskind AA et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation, 1989; 79: 920-928. (Pubitemid 19100552)
22. Barbash GI, Reiner J, White HD et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol, 1995; 26: 1222-1229.
23. Vlaar PJ, Svilaas T, Damman K et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation, 2008; 118: 1828-1836.
24. Schulz S, Birkmeier KA, Ndrepepa G et al. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clin Res Cardiol, 2010; 99: 795-802.
25. Dudek D, Rakowski T, Bartus S et al. Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention. J Thromb Thrombolysis, 2010; 30: 347-353.
26. Meneveau N, Séronde MF, Descotes-Genon V et al. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients. Clin Res Cardiol, 2009; 98: 257-264.